We are live on ! Find out more
PI

Pennant Investors Portfolio holdings

AUM $361M
1-Year Est. Return 134.26%
This Fund
S&P 500
This Quarter Est. Return
+13.88%
1 Year Est. Return
+134.26%
3 Year Est. Return
+359.01%
5 Year Est. Return
+289.76%
10 Year Est. Return
AUM
$458M
AUM Growth
+$181M
Cap. Flow
+$134M
Cap. Flow %
29.16%
Top 10 Hldgs %
94.72%
Holding
45
New
32
Increased
1
Reduced
Closed
1

Top Sells

Rank Stock Value
1
DISH
DISH Network Corp.
DISH
+$24.3M

Sector Composition

Rank Sector Weight
1 Communication Services 19.22%
2 Consumer Discretionary 16.46%
3 Technology 16.31%
4 Industrials 9.34%
5 Energy 4.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AAPL icon
1
PUT
Apple
AAPL
$4.54T
$121M 26.48%
+630,000
New +$116M
AMZN icon
2
Amazon
AMZN
$2.92T
$52.9M 11.54%
348,000
GOOGL icon
3
Alphabet (Google) Class A
GOOGL
$4.36T
$52.4M 11.44%
375,000
MSFT icon
4
Microsoft
MSFT
$3.45T
$48.5M 10.59%
129,000
TDG icon
5
TransDigm Group
TDG
$70.2B
$42.5M 9.28%
42,000
ECHO
6
EchoStar
ECHO
$24.4B
$35.7M 7.79%
+2,153,209
New +$27.7M
MU icon
7
Micron Technology
MU
$930B
$26.1M 5.7%
306,000
ODP
8
DELISTED
ODP
ODP
$22.5M 4.92%
400,000
AR icon
9
Antero Resources
AR
$11.1B
$20.7M 4.52%
913,000
AR icon
10
CALL
Antero Resources
AR
$11.1B
$11.3M 2.48%
500,000
PRM icon
11
Perimeter Solutions
PRM
$4.99B
$10.6M 2.31%
2,300,000
+700,000
+44% +$2.69M
ALT icon
12
Altimmune
ALT
$552M
$1.24M 0.27%
+109,800
New +$458K
KYNB
13
Kyntra Bio
KYNB
$27.2M
$681K 0.15%
+30,736
New +$464K
NRIX icon
14
Nurix Therapeutics
NRIX
$2.41B
$586K 0.13%
+56,800
New +$389K
CHRS icon
15
Coherus Oncology
CHRS
$217M
$560K 0.12%
+168,100
New +$450K
ARQT icon
16
Arcutis Biotherapeutics
ARQT
$3.36B
$552K 0.12%
+170,900
New +$465K
FATE icon
17
Fate Therapeutics
FATE
$286M
$546K 0.12%
+146,100
New +$345K
IGMS
18
DELISTED
IGM Biosciences
IGMS
$539K 0.12%
+64,900
New +$377K
ALLK
19
DELISTED
Allakos
ALLK
$508K 0.11%
+186,100
New +$419K
TVTX icon
20
Travere Therapeutics
TVTX
$5.2B
$502K 0.11%
+55,800
New +$406K
ETNB
21
DELISTED
89bio
ETNB
$497K 0.11%
+44,500
New +$409K
ZNTL icon
22
Zentalis Pharmaceuticals
ZNTL
$337M
$491K 0.11%
+32,400
New +$473K
RLAY icon
23
Relay Therapeutics
RLAY
$4.1B
$467K 0.1%
+42,400
New +$358K
RCUS icon
24
Arcus Biosciences
RCUS
$3.55B
$453K 0.1%
+23,700
New +$379K
MGNX icon
25
MacroGenics
MGNX
$235M
$421K 0.09%
+43,800
New +$303K

Similar funds

Pennant Investors's Q4 2023 Portfolio in Review

As of Q4 2023, Pennant Investors held 45 positions worth $458M, up 65% from $277M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Pennant Investors deployed $134M of net new capital in Q4 2023, opening 32 new positions and adding to 1 existing holding. Its largest new stake was EchoStar: 2,153,209 shares worth $35.7M.

By sector, the portfolio is most concentrated in Communication Services at 19% of assets, down from 27% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the most notable exit was DISH Network Corp., an estimated $24.3M sold.

  • Pennant Investors's largest Q4 2023 buy was EchoStar: 2,153,209 shares worth $35.7M.
  • Pennant Investors added most to Perimeter Solutions in Q4 2023, an estimated $2.69M increase.
  • Pennant Investors fully exited DISH Network Corp. in Q4 2023, selling an estimated $24.3M.
  • Pennant Investors's ten largest holdings make up 95% of its $458M portfolio in Q4 2023.
  • Pennant Investors opened 32 new positions and closed 1 in Q4 2023.
  • Pennant Investors's portfolio value rose 65% quarter-over-quarter to $458M.

Based on Pennant Investors's 13F filing for Q4 2023, filed 14 Feb 2024.